Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?

Hdl Handle:
http://hdl.handle.net/10147/207589
Title:
Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?
Authors:
Duffy, Michael J
Affiliation:
Department of Pathology and Laboratory Medicine, St Vincent's University, Hospital, Dublin, Ireland. Michael.J.Duffy@ucd.ie
Citation:
Ann Clin Biochem. 2011 Jul;48(Pt 4):310-6. Epub 2011 Apr 27.
Journal:
Annals of clinical biochemistry
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207589
DOI:
10.1258/acb.2011.010273
PubMed ID:
21525152
Abstract:
Although widely used, the value of prostate-specific antigen (PSA) in screening asymptomatic men for prostate cancer is controversial. Reasons for the controversy relate to PSA being less than an ideal marker in detecting early prostate cancer, the possibility that screening for prostate cancer may result in the overdetection and thus overtreatment of indolent disease and the lack of clarity as to the definitive or best treatment for men diagnosed with localized prostate cancer. Although the results from some randomized prospective trials suggest that screening with PSA reduces mortality from prostate cancer, the overall benefit was modest. It is thus currently unclear as to whether the modest benefit of reduced mortality outweighs the harms of overdetection and overtreatment. Thus, prior to undergoing screening for prostate cancer, men should be informed of the risks and benefits of early detection. Newly emerging markers that may complement PSA in the early detection of prostate cancer include specific isoforms of PSA and PCA3.
Language:
eng
MeSH:
Antigens, Neoplasm/blood; *Early Detection of Cancer; Great Britain; Humans; Male; Prostate-Specific Antigen/*blood/chemistry/genetics; Prostatic Neoplasms/*diagnosis/epidemiology; Randomized Controlled Trials as Topic; Tumor Markers, Biological/*blood/chemistry/genetics
ISSN:
1758-1001 (Electronic); 0004-5632 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorDuffy, Michael Jen_GB
dc.date.accessioned2012-02-01T10:32:13Z-
dc.date.available2012-02-01T10:32:13Z-
dc.date.issued2012-02-01T10:32:13Z-
dc.identifier.citationAnn Clin Biochem. 2011 Jul;48(Pt 4):310-6. Epub 2011 Apr 27.en_GB
dc.identifier.issn1758-1001 (Electronic)en_GB
dc.identifier.issn0004-5632 (Linking)en_GB
dc.identifier.pmid21525152en_GB
dc.identifier.doi10.1258/acb.2011.010273en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207589-
dc.description.abstractAlthough widely used, the value of prostate-specific antigen (PSA) in screening asymptomatic men for prostate cancer is controversial. Reasons for the controversy relate to PSA being less than an ideal marker in detecting early prostate cancer, the possibility that screening for prostate cancer may result in the overdetection and thus overtreatment of indolent disease and the lack of clarity as to the definitive or best treatment for men diagnosed with localized prostate cancer. Although the results from some randomized prospective trials suggest that screening with PSA reduces mortality from prostate cancer, the overall benefit was modest. It is thus currently unclear as to whether the modest benefit of reduced mortality outweighs the harms of overdetection and overtreatment. Thus, prior to undergoing screening for prostate cancer, men should be informed of the risks and benefits of early detection. Newly emerging markers that may complement PSA in the early detection of prostate cancer include specific isoforms of PSA and PCA3.en_GB
dc.language.isoengen_GB
dc.subject.meshAntigens, Neoplasm/blooden_GB
dc.subject.mesh*Early Detection of Canceren_GB
dc.subject.meshGreat Britainen_GB
dc.subject.meshHumansen_GB
dc.subject.meshMaleen_GB
dc.subject.meshProstate-Specific Antigen/*blood/chemistry/geneticsen_GB
dc.subject.meshProstatic Neoplasms/*diagnosis/epidemiologyen_GB
dc.subject.meshRandomized Controlled Trials as Topicen_GB
dc.subject.meshTumor Markers, Biological/*blood/chemistry/geneticsen_GB
dc.titleProstate-specific antigen: does the current evidence support its use in prostate cancer screening?en_GB
dc.contributor.departmentDepartment of Pathology and Laboratory Medicine, St Vincent's University, Hospital, Dublin, Ireland. Michael.J.Duffy@ucd.ieen_GB
dc.identifier.journalAnnals of clinical biochemistryen_GB
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.